Phase 3 Readout
VNDA: Phase 3 Topline: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in
September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- Vanda Pharmaceuticals Inc. (VNDA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in
- Indication
- Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders